Hyperion Therapeutics, which is focused on the treatment of orphan diseases of the liver relating to the urea cycle, raised $50 million by offering 5 million shares at $10.00, below the range of $11.00 to $13.00. Because Hyperion had planned to offer only 4.2 million shares, there was no change in proceeds raised. Hyperion Therapeutics plans to list on the NASDAQ under the symbol HPTX. Leerink Swann and Cowen & Company acted as lead managers on the deal.
